Impact of Long-Term Cinacalcet, Ibandronate or Teriparatide Therapy on Bone Mineral Density of Hemodialysis Patients: A Pilot Study

Cinacalcet (Sensipar) Provides no Measurable Clinical Benefits for Patients with Primary Hyperparathyroidism and may Accelerate Bone Loss with Prolonged Use

(2011) James Norman et al.   ANNALS OF SURGICAL ONCOLOGY

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism

(2011) H.H. Malluche et al.   CLINICAL NEPHROLOGY

Reducing the Risk of Re-Fracture in the Dialysis Population: Is it Time to Consider Therapy with PTH Analogues?

(2011) Sophie A. Jamal et al.   SEMINARS IN DIALYSIS

Comparison of Active Vitamin D Compounds and a Calcimimetic in Mineral Homeostasis

(2010) L. Nguyen-Yamamoto et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1–34): A Pilot Study

(2010) Daniel Cejka et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study

(2009) Munro Peacock et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Review article: Bone density in patients with chronic kidney disease stages 4-5

(2009) SUSAN M OTT   NEPHROLOGY

A reference standard for the description of osteoporosis

(2007) John A. Kanis et al.   BONE